We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies as set out in our cookie notice.
Takeda proudly continues advancing and supporting the hemophilia A community.See howFor U.S. healthcare professionals only
Takeda proudly continues advancing and supporting the hemophilia A community.See howFor U.S. healthcare professionals only
In the hemophilia A community, no two patients are the same
When finding a treatment for hemophilia A, your patients' individual needs as well as their lives outside the clinic should be taken into account.1
There are many characteristics that make each patient different1,2:
Physical activity and lifestyle
Bleeding phenotype
Pharmacokinetic (PK) profile
Infusion dose and frequency
Adherence and prophylaxis
Annualized bleed rate (ABR) and ABR for joint bleeds
Personal goals
Baseline characteristics (eg, age, weight)
Living with hemophilia A will always be an undeniable part of their reality—both the welcome and unwelcome moments. Your patients need treatment options that can help them navigate the many complexities of real life with hemophilia A.
Hear from a peer about the ADVATE active patient type
Watch Jonathan C. Roberts, MD, discuss ADVATE as a personalized treatment option that can help protect against bleeds for his patient living with hemophilia A who has an active lifestyle. Learn more about the active patient type with a helpful brochure available here.
Hear from a peer about the ADVATE high-risk bleed patient type
Watch Mark Reding, MD, discuss ADVATE as a prophylactic treatment option for his Hemophilia A patient who is at a high risk for bleeds. Learn more about high-risk bleed patients in a helpful brochure available here.
Selected Important Risk Information
Warnings & Precautions
Neutralizing antibodies (inhibitors) have been reported following administration of ADVATE predominantly in previously untreated patients (PUPs) and previously minimally treated patients (MTPs). Monitor all patients for the development of factor VIII inhibitors by appropriate clinical observation and laboratory testing. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an expected dose, perform an assay that measures factor VIII inhibitor concentration.
Please see additional detailed important risk information below.
ADVATE has 15+ years of experience treating hemophilia A in the real world3
ADVATE is a third-generation, full-length molecule, similar to the factor VIII that occurs naturally in the body.3,4
Established formulation
with a later generation plasma/ albumin-free recombinant factor VIII.3,4
Proven
clinical record.5-7
The most widely used
factor VIII product with 33 billion IUs sold globally.8 Based on units sold, as of February 2019.
Extensively studied
with evidence spanning over 15 years with 15 prospective studies.3,4,8
Committed to advancing hemophilia A care
In 2003, ADVATE became the first recombinant factor VIII treatment free of blood-based additives. Since then, TAKEDA has made advancements with flexible dosing options, reconstitution with BAXJECT® system, and the introduction of myPKFiT® for PK-guided personalized dosing.3,8
2003
ADVATE [Antihemophilic Factor (Recombinant)]: first recombinant factor VIII (rFVIII) made without added human or animal proteins.3,8
2007
First rFVIII 3000-IU single-vial dose.8
2011
First and only rFVIII with physical health-related quality-of-life results in the Prescribing Information.3
2014
ADVATE with BAXJECT III® reconstitution system.8
2006
BAXJECT II needleless transfer device.8
2010
First and only rFVIII 1700-IU single-vial dose.8
2012
First and only rFVIII 4000-IU single-vial dose and 2-mL diluent option (250 IU, 375 IU, 500 IU, 750 IU, 1000 IU, 1500 IU, and 1700 IU).3,8
2018
myPKFiT for ADVATE receives approval from the FDA for patients 16 and older.8
CONTRAINDICATIONS: Patients who have life-threatening hypersensitivity reactions, including anaphylaxis, to mouse or hamster protein or other constituents of the product.
Valentino LA. Considerations in individualizing prophylaxis in patients with haemophilia A. Haemophilia. 2014;20(5):6.
Petrini P, Valentino LA, Gringeri A, Re WM, Ewenstein B. Individualizing prophylaxis in hemophilia: a review. Expert Rev Hematol. 2015;8(2):237-246. doi:10.1586/17474086.2015.1002465
Advate. Prescribing information. Baxalta US Inc; 2018.
Grillberger L, Kreil TR, Nasr S, Reiter M. Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol J. 2009;4(2):186-201. doi:10.1002/biot.200800241
Auerswald G, Thompson AA, Recht M, et al. Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A. Thromb Haemost. 2012;107(6):1072-1082. doi:10.1160/TH11-09-0642
Khair K, Mazzucconi MG, Parra R, et al. Pattern of bleeding in a large prospective cohort of haemophilia A patients: a three-year follow-up of the AHEAD (Advate in HaEmophilia A outcome Database) study. Haemophilia. 2018;24(1):85-96. doi:10.1111/hae.13361
Valentino LA, Mamonov V, Hellmann A, et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost. 2012;10(3):359-367. Published correction appears in J Thromb Haemost. 2012;10(6):1204.
Takeda data on file.
You are now leaving ADVATEPro.com
Takeda does not review, endorse, or control the content of any non-Takeda site. Takeda is not responsible for the accuracy, content, practices, or standards of any non-Takeda resources accessed through a link on this site.